Table 1.

Patient characteristics.

CharacteristicsFatigue: None to Mild, VAS Score < 57, n = 520Fatigue: Moderate to Severe, VAS Score ≥ 57, n = 542p
nn
Female, n (%)253 (48.7)520358 (66.1)542< 0.001
Age, yrs53.0 (44.0–62.0)52052.0 (42.8–60.0)5420.070
Disease duration, yrs6.0 (3.0–11.5)4495.0 (2.0–10.0)4560.022
Previous use of DMARD, n (%):5205420.046
  None449 (86.3)443 (81.7)
  144 (8.5)50 (9.2)
  226 (5.0)49 (9.0)
  3+1 (0.1)0 (0.0)
Use of MTX, n (%)316 (60.8)520313 (57.7)5420.319
Concomitant corticosteroid, n (%)6 (1.2)52029 (5.4)542< 0.001
Biological treatment, status, n (%)520542< 0.001
  Never treated with biologicals272 (52.3)279 (51.5)
  In current treatment224 (43.1)195 (36.0)
  Previous use24 (4.6)68 (12.5)
SJC, 0–28*0.47 ± 1.34550.94 ± 2.2459< 0.001
TJC, 0–28*1.73 ± 3.64565.0 ± 6.4469< 0.001
CRP, mg/l3.0 (1.0–6.0)4214.0 (2.0–7.0)4640.008
Patient pain assessment, 0–100 mm VAS25.0 (15.0–38.0)52066.0 (49.0–78.0)542< 0.001
PtGA, 0–100 mm VAS27.0 (15.0–43.0)52075.5 (61.0–86.0)542< 0.001
PGA, 0–100 mm VAS7.0 (3.0–15.0)43214.0 (7.0–14.0)438< 0.001
PDQ score9.0 (6.0–14.0)52017.0 (13.0–23.0)542< 0.001
DAS28-CRP2.3 (1.8–2.9)4003.5 (2.6–4.4)418< 0.001
HAQ score, 0–30.4 (0.1–0.8)5071.1 (0.8–1.6)530< 0.001
  • Unless otherwise stated, data were given as median with interquartile range.

  • * SJC and TJC given as mean ± SD. VAS: visual analog scale; DMARD: disease-modifying antirheumatic drugs; MTX: methotrexate; PDQ: Pain Detect Questionnaire; CRP: C-reactive protein; DAS28-CRP: 28-joint count Disease Activity Score using CRP; HAQ: Health Assessment Questionnaire; SJC: swollen joint count; TJC: tender joint count; PtGA: patient’s global assessment; PGA: physician’s global assessment.